Table 2 Stratified analysis of FGFR4 G388R or V10I polymorphisms on susceptibility of cancer.
From: Effects of FGFR4 G388R, V10I polymorphisms on the likelihood of cancer
Variables | Na | Case/control | M-allele versus W-allele | MW versus WW | MM versus WW | MM + MW versus WW | MM versus MW + WW | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
OR (95%CI) | Pheter | P | OR (95%CI) | Pheter | P | OR (95%CI) | Pheter | P | OR (95%CI) | Pheter | P | OR (95%CI) | Pheter | P | |||
G388R | |||||||||||||||||
Total | 30 | 9416/11187 | 1.06 (0.98–1.15) | < 0.001 | 0.123 | 0.99 (0.90–1.09) | 0.003 | 0.820 | 1.21 (1.03–1.43) | < 0.001 | 0.020 | 1.03 (0.94–1.14) | < 0.001 | 0.526 | 1.21 (1.04–1.41) | < 0.001 | 0.012 |
Ethnicity | |||||||||||||||||
Asian | 13 | 5045/5338 | 1.12 (0.99–1.26) | < 0.001 | 0.078 | 1.03 (0.89–1.18) | 0.011 | 0.715 | 1.29 (1.01–1.66) | < 0.001 | 0.043 | 1.09 (0.94–1.26) | 0.002 | 0.247 | 1.28 (1.02–1.60) | < 0.001 | 0.034 |
European | 15 | 4157/5684 | 1.01 (0.90–1.13) | 0.013 | 0.876 | 0.94 (0.81–1.09) | 0.016 | 0.396 | 1.10 (0.94–1.28) | 0.198 | 0.238 | 0.97 (0.84–1.12) | 0.010 | 0.669 | 1.08 (0.93–1.26) | 0.296 | 0.306 |
African | 1 | 146/80 | 1.14 (0.66–1.98) | – | 0.635 | 1.25 (0.66–2.38) | – | 0.496 | 0.87 (0.14–5.33) | – | 0.876 | 1.21 (0.65–2.25) | – | 0.544 | 0.82 (0.13–5.00) | – | 0.828 |
LA | 1 | 68/85 | 0.97 (0.57–1.64) | – | 0.905 | 0.90 (0.46–1.73) | – | 0.743 | 1.21 (0.23–6.31) | – | 0.825 | 0.92 (0.48–1.75) | – | 0.799 | 1.26(0.25–6.46) | – | 0.780 |
Cancer type | |||||||||||||||||
Prostate cancer | 6 | 2618/1992 | 1.17 (1.07–1.29) | 0.183 | 0.001 | 1.16 (1.02–1.32) | 0.714 | 0.025 | 1.60 (0.98–2.61) | 0.020 | 0.058 | 1.20 (1.06–1.35) | 0.892 | 0.004 | 1.56 (0.92–2.65) | 0.004 | 0.103 |
Cervical cancer | 2 | 388/497 | 1.12 (0.93–1.36) | 0.178 | 0.225 | 1.06 (0.77–1.45) | 0.073 | 0.729 | 1.26 (0.88–1.82) | 0.209 | 0.211 | 1.12 (0.83–1.51) | 0.071 | 0.454 | 1.21 (0.89–1.65) | 0.756 | 0.228 |
OSCC | 2 | 1105/1291 | 0.87 (0.78–0.98) | 0.188 | 0.019 | 0.97 (0.79–1.18) | 0.164 | 0.726 | 1.01 (0.44–2.32) | 0.046 | 0.984 | 0.90 (0.75–1.09) | 0.806 | 0.284 | 1.13 (0.40–3.21) | 0.008 | 0.820 |
HCC | 3 | 1058/1423 | 1.04 (0.93–1.16) | 0.241 | 0.518 | 1.00 (0.83–1.20) | 0.127 | 0.991 | 1.09 (0.86–1.37) | 0.341 | 0.478 | 1.03 (0.86–1.22) | 0.139 | 0.769 | 1.09 (0.89–1.33) | 0.656 | 0.423 |
Breast cancer | 6 | 1489/1519 | 1.26 (1.13–1.41) | 0.622 | < 0.001 | 1.25 (1.07–1.47) | 0.186 | 0.005 | 1.73 (1.35–2.20) | 0.960 | < 0.001 | 1.32 (1.14–1.54) | 0.197 | < 0.001 | 1.46 (1.17–1.83) | 0.986 | 0.001 |
Lung cancer | 2 | 398/501 | 0.85 (0.69–1.05) | 0.587 | 0.138 | 0.79 (0.60–1.05) | 0.800 | 0.099 | 0.82 (0.50–1.34) | 0.312 | 0.435 | 0.80 (0.61–1.04) | 0.932 | 0.091 | 0.91 (0.57–1.47) | 0.267 | 0.704 |
CRC | 3 | 346/2003 | 0.98 (0.80–1.19) | 0.691 | 0.820 | 0.89 (0.67–1.17) | 0.972 | 0.387 | 1.08 (0.69–1.69) | 0.521 | 0.730 | 0.9 2 (0.71–1.19) | 0.901 | 0.518 | 1.14 (0.74–1.76) | 0.496 | 0.551 |
Other cancers | 6 | 2014/1961 | 0.96 (0.74–1.24) | < 0.001 | 0.743 | 0.85 (0.63–1.15) | 0.003 | 0.301 | 1.04 (0.67–1.63) | 0.003 | 0.854 | 0.89 (0.65–1.23) | < 0.001 | 0.496 | 1.13 (0.78–1.64) | 0.012 | 0.510 |
V10I | |||||||||||||||||
Total | 7 | 4377/4992 | 0.94 (0.85–1.04) | 0.049 | 0.227 | 0.97 (0.89–1.07) | 0.169 | 0.601 | 0.92 (0.72–1.17) | 0.020 | 0.488 | 0.95 (0.87–1.04) | 0.147 | 0.300 | 0.90 (0.74–1.11) | 0.020 | 0.328 |
Ethnicity | |||||||||||||||||
Asian | 4 | 2218/2837 | 0.93 (0.79–1.10) | 0.011 | 0.408 | 1.05 (0.91–1.21) | 0.140 | 0.493 | 0.87 (0.62–1.22) | 0.009 | 0.423 | 0.98 (0.78–1.23) | 0.049 | 0.844 | 0.85 (0.66–1.08) | 0.021 | 0.184 |
European | 2 | 2012/2075 | 0.97 (0.87–1.07) | 0.407 | 0.516 | 0.92 (0.80–1.05) | 0.220 | 0.200 | 1.05 (0.80–1.38) | 0.994 | 0.728 | 0.93 (0.82–1.06) | 0.269 | 0.293 | 1.08 (0.83–1.42) | 0.825 | 0.563 |
African | 1 | 147/80 | 0.81 (0.35–1.84) | – | 0.609 | 0.80 (0.34–1.86) | – | 0.598 | NA | 0.80 (0.34–1.86) | – | 0.598 | NA | ||||
Cancer type | |||||||||||||||||
Prostate cancer | 2 | 1406/1334 | 0.93 (0.82–1.06) | 0.732 | 0.276 | 0.86 (0.73–1.01) | 0.861 | 0.067 | 1.05 (0.74–1.49) | – | 0.780 | 0.88 (0.75–1.03) | 0.811 | 0.114 | 1.11 (0.79–1.57) | – | 0.555 |
Cervical cancer | 1 | 227/335 | 1.09 (0.86–1.39) | – | 0.461 | 0.93 (0.62–1.40) | – | 0.735 | 1.20 (0.75–1.91) | – | 0.450 | 1.01 (0.69–1.48) | – | 0.939 | 1.25 (0.85–1.85) | – | 0.257 |
OSCC | 1 | 955/1191 | 0.96 (0.85–1.09) | – | 0.542 | 1.19 (0.96–1.47) | – | 0.118 | 0.94 (0.73–1.20) | – | 0.596 | 1.10 (0.90–1.34) | – | 0.375 | 0.83 (0.68–1.01) | – | 0.066 |
Breast cancer | 1 | 747/716 | 0.75 (0.65–0.87) | – | < 0.001 | 0.83 (0.63–1.08) | – | 0.165 | 0.55 (0.40–0.74) | – | < 0.001 | 0.72 (0.56–0.93) | – | 0.012 | 0.63 (0.50–0.79) | – | < 0.001 |
HCC | 1 | 289/595 | 1.02 (0.83–1.24) | – | 0.870 | 1.24 (0.87–1.76) | – | 0.228 | 1.03 (0.68–1.55) | – | 0.880 | 1.17 (0.84–1.63) | – | 0.349 | 0.89 (0.64–1.25) | – | 0.499 |
Skin cancer | 1 | 753/821 | 1.02 (0.86–1.21) | – | 0.802 | 1.02 (0.82–1.26) | – | 0.865 | 1.05 (0.67–1.64) | – | 0.835 | 1.02 (0.83–1.25) | – | 0.828 | 1.04 (0.67–1.62) | – | 0.855 |
